Genetic association of cytokine DNA polymorphisms with head and neck cancer

Oral Oncology

Volumn 44, Issue 12, 2008, Pages 1093-1099

  Serefoglou, Zoe ^a   Yapijakis, Christos ^a   Nkenke, Emeka ^b   Vairaktaris, Eleftherios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiogenesis; Cytokines; DNA polymorphisms; Genetic association; Head and neck cancer; Inflammation; Interleukins; Tumor necrosis factors

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

CANCER RISK; DNA POLYMORPHISM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HUMAN; MOUTH CARCINOMA; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

CARCINOMA, SQUAMOUS CELL; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HEAD AND NECK NEOPLASMS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 56549093779     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.02.012     Document Type: Review

References (99)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Silverman Jr. S. Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 132 (2001) 7S-11S
3. Burtness B. Head and neck cancer. Encyclopedia Cancer 2 (2002) 339-346
4. Alvarez Marcos C.A., Llorente Pendás J.L., Franco Gutiérrez V., Hermsen M.A., Franco Albalad M.P., Fernández Espina H., et al. Second primary tumors in head and neck cancer. Acta Otorrinolaringol Esp 57 10 (2006) 462-466
5. Williams H.K. Molecular pathogenesis of oral squamous cell carcinoma. J Clin Pathol Mol Pathol 53 (2000) 165-172
6. Tiret L. Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc 61 4 (2002) 457-463
7. Wünsch Filho V., and Zago M.A. Modern cancer epidemiological research: genetic polymorphisms and environment. Rev Saude Publica 39 3 (2005) 490-497
8. Tsigris C., Chatzitheofylaktou A., Xiromeritis C., Nikiteas N., and Yannopoulos A. Genetic association studies in digestive system malignancies. Anticancer Res 27 5B (2007) 3577-3587
9. Casciari J.J., Sato H., Durum S.K., Fiege J., and Weinstein J.N. Reference databases of cytokine structure and function. Cancer Chemother Biologic Response Modifiers 16 (1996) 315-346
10. Balkwill F.R., and Burke F. The cytokine network. Cell Biol Int 24 9 (2000) 299-304
11. Dinarello C.A. Interleukin-18, a proinflammatory cytokine. Euro Cytokine Netw 11 3 (2000) 483-486
12. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol 12 1 (2000) 59-63
13. Elias J.A., and Zitnik R.J. Cytokine-cytokine interactions in the context of cytokine networking. Am J Respirat Cell Mol Biol 7 (1992) 365-367
14. Salazar-Onfray F., López M.N., and Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18 1-2 (2007) 171-182
15. Fraser J.K., Lill M.C., and Figlin R.A. The biology of the cytokine sequence cascade. Semin Oncol 23 (1996) 2-8
16. Kemp Z., Thirlwell C., Sieber O., Silver A., and Tomlinson I. An update on the genetics of colorectal cancer. Hum Mol Genet 13 2 (2004) 177-185
17. Turnbull C., and Hodgson S. Genetic predisposition to cancer. Clin Med 5 5 (2005) 491-498
18. El-Omar E.M. Role of host genes in sporadic gastric cancer. Best Pract Res Clin Gastroenterol 20 4 (2006) 675-686
19. Arlt A., Vorndamm J., Muerkoster S., Yu H., Schmidt W.E., Folsch U.R., et al. Autocrine production of interleukin 1 beta confers constitutive nuclear factor kappa B activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62 3 (2002) 910-916
20. Saijo Y., Tanaka M., Miki M., Usui K., Suzuki T., Maemondo M., et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. Immunology 169 1 (2002) 469-475
21. Klein B., Zhang X.G., Jourdan M., Content J., Houssiau F., Aarden L., et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73 2 (1989) 517-526
22. Voorzanger N., Touitou R., Garcia E., Delecluse H.J., Rousset F., Joab I., et al. Interleukin- (IL-10) and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56 23 (1996) 5499-5505
23. Okamoto M., Kawamata H., Kawai K., and Oyasu R. Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by interleukin 6. Cancer Res 55 20 (1995) 4581-4585
24. Landi S., Moreno V., Gioia-Patricola L., Guino E., Navarro M., de Oca J., et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis activated receptor gamma with colorectal cancer. Cancer Res 63 13 (2003) 3560-3566
25. Luca M., Huang S., Gershenwald J.E., Singh R.K., Reich R., and Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 151 4 (1997) 1105-1113
26. Huang S., Mills L., Mian B., Tellez C., McCarty M., Yang X.D., et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161 1 (2002) 125-134
27. Niu J., Li Z., Peng B., and Chiao P.J. Identification of an autoregulatory feedback pathway involving interleukin-1 alpha in induction of constitutive NF-kappa B activation in pancreatic cancer cells. J Biol Chem 279 16 (2004) 16452-16456
28. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. IL-1 beta-mediated up-regulation of HIF-1 alpha via an NFkappa B/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB 17 14 (2003) 2115-2117
29. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., Fuentes A.M., Anasagasti M.J., Martin J., et al. IL-18 regulates IL-1 beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci USA 97 2 (2000) 734-739
30. al-Wabel A., al-Knawy B., and Raziuddin S. Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis. Clin Immunol Immunopathol 74 (1995) 231-235
31. Tsai C.C., Chen C.C., Lin C.C., Chen C.H., Lin T.S., and Shieh T.Y. Interleukin-1 beta in oral submucous fibrosis, verrucous hyperplasia and squamous cell carcinoma tissues. Kaohsiung J Med Sci 15 (1999) 513-519
32. Srivani R., and Nagarajan B. A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 13 (2003) 331-339
33. Michalaki V., Syrigos K., Charles P., and Waxman J. Serum levels of IL-6 and TNF-αlpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 (2004) 2312-2316
34. Lokshin A.E., Winans M., Landsittel D., Marrangoni A.M., Velikokhataya L., Modugno F., et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 102 2 (2006) 244-251
35. Ye Z.B., Ma T., Li H., Jin X.L., and Xu H.M. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol 13 11 (2007) 1747-1751
36. Hermann F., Andreeff M., Gruss H.J., Brach M.A., Lübbert M., and Mertelsmann R. Interleukin-4 inhibits growth of multiple myelomas by suppressing Interleukin-6 expression. Blood 78 (1991) 2070-2074
37. Toi M., Bicknell R., and Harris A.L. Inhibition of colon and breast carcinoma growth by interleukin-4. Cancer Res 52 (1992) 275-279
38. Obiri N.I., Siegel J., Varricchio F., and Puri R.K. Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol 95 (1994) 148-155
39. Takeshi U., Sadar M.D., Suzuki H., Akakura K., Sakamoto S., Shimbo M., et al. Interleukin-4 in patients with prostate cancer. Anticancer Res 25 (2005) 4595-4598
40. Lan Q., Zheng T., Rothman N., Zhang Y., Wang S.S., Shen M., et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107 10 (2006) 4101-4108
41. Fortis C., Foppoli M., Gianotti L., Galli L., Citterio G., Consogno G., Gentilini O., and Braga M. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 104 (1996) 1-5
42. Bazzoni F., and Beutler B. The tumor necrosis factor ligand and receptor families. New Eng J Med 334 (1996) 1717-1725
43. Wilson A.G., di Giovine F.S., and Duff G.W. Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. J Inflamm 45 (1995) 1-12
44. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., et al. Human lung carcinomas express Fas ligand. Cancer Res 57 (1997) 1007-1012
45. Shiraki K., Tsuji N., Shioda T., Isselbacher K.J., and Takahashi H. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci USA 94 (1997) 6420-6425
46. Boehm U., Klamp T., Groot M., and Howard J.C. Cellular responses to interferon-γ. Annu Rev Immunol 15 (1997) 749-795
47. Pinedo H.M., Verheul H.M.W., D' Amato R.J., and Folkman J. Involvement of platelets in tumor angiogenesis?. Lancet 352 (1998) 1775-1777
48. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
49. Rich J., Borton A., and Wang X. Transforming growth factor-beta signalling in cancer. Microsc Res Tech 52 (2001) 363-373
50. Siegel P.M., and Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 3 (2003) 807-821
51. de Caestecker M.P., Piek E., and Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92 (2000) 1388-1402
52. Benson J.R. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5 4 (2004) 229-239
53. Woods K.V., El-Naggar A., Clayman G.L., and Grimm E.A. Variable expression of cytokines in head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58 (1998) 3132-3141
54. Chen Z., Colon I., Ortiz N., Callister M., Dong G., Pegram M.Y., et al. Effects of interleukin-1 alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 58 (1998) 3668-3676
55. Chen Z., Malhotra P.S., Thomas G.R., Ondrey F.G., Duffey D.C., Smith C.W., et al. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5 (1999) 1369-1379
56. Jablonska E., Piotrowski L., and Grabowska Z. Serum levels of IL-1b, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res 3 (1997) 126-129
57. Watanabe H., Iwase M., Ohashi M., and Nagumo M. Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38 (2002) 670-679
58. Karcher J., Reisser C., Daniel V., and Herold-Mende C. Cytokine expression of transforming growth factor-beta2 and interleukin-10 in squamous cell carcinomas of the head and neck. Comparison of tissue expression and serum levels. Otolaryngology (HNO) 47 (1999) 879-884
59. Fujieda S., Sunaga H., Tsuzuki H., Fank G.K., and Saito H. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett 136 (1999) 1-9
60. Beppu M., Ikebe T., and Shirasuna K. The inhibitory effects of immunosuppressive factors, dexamethasone and interleukin-4, on NF-κB-mediated protease production by oral cancer. Biochim Biophys Acta 1586 (2002) 11-22
61. Deans D.A., Wigmore S.J., Gilmour H., Paterson-Brown S., Ross J.A., and Fearon K.C. Elevated tumour interleukin-1 beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95 (2006) 1568-1575
62. Diakowska D., Markocka-Maczka K., Grabowski K., and Lewandowski A. Serum interleukin-12 and interleukin-18 levels in patients with esophageal squamous cell carcinoma. Exp Oncol 28 4 (2006) 319-322
63. Kozlowski M., Kowalczuk O., Sulewska A., Dziegielewski P., Lapuć G., Laudański W., et al. Serum soluble Fas ligand (sFASL) in patients with primary squamous cell carcinoma of the esophagus. Cancer 92 2 (2001) 287-293
64. Rees J.R.E., Onwuegbusi B.A., Save V.E., Alderson D., and Fitzgerald R.C. In vivo and in vitro evidence for transforming growth factor-β1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 66 (2006) 9583-9590
65. Pratesi C., Bortolin M.T., Bidoli E., Tedechi R., Vaccher E., Dolcetti R., et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal. Cancer Immunol Immunother 55 (2006) 23-30
66. Myers J.N., Yasumura S., Suminami Y., Hirabayashi H., Lin W.C., Johnson J.T., et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2 (1996) 127-135
67. Riedel F., Adam S., Feick P., Haas K., Götte S., and Hörmann K. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 13 2 (2004) 267-272
68. Hirschhorn J.N., Lohmueller K., Byrne E., and Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 4 2 (2002) 45-61
69. Turnbull C., and Hodgson S. Genetic predisposition to cancer. Clin Med 5 5 (2005) 491-498
70. Cooper D.N., Nussbaum R.L., and Krawczak M. Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 110 3 (2002) 207-208
71. Howell W.M., and Rose-Zerilli M.J. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137 (2007) 194-199
72. Liu C.J., Wong Y.K., Chang K.W., Chang H.C., Liu H.F., and Lee Y.J. Tumor necrosis factor-α promoter polymorphism is associated with susceptibility to oral squamous cell carcinoma. J Oral Pathol Med 34 (2005) 608-612
73. Vairaktaris E., Yiannopoulos A., Vylliotis A., Yapijakis C., Derka S., Vassiliou S., et al. Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21 4 (2006) 246-250
74. Vairaktaris E., Yapijakis C., Serefoglou Z., Derka S., Vassiliou S., Nkenke E., et al. The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33 4 (2007) 504-507
75. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, et al. Gene expression polymorphism of interleukin-10 is associated with risk for oral squamous carcinoma. Anticancer Res [in press].
76. Yapijakis C, Vairaktaris E, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, et al. Association of tumor necrosis factor alpha -308 G/A and beta 252 G/A polymorphisms with increased risk for oral cancer. Int J Biol Markers [in press].
77. Chiu C.J., Chiang C.P., Chang M.L., Chen H.M., Hahn L.J., Hsieh L.L., et al. Association between genetic polymorphism of tumor necrosis factor-alpha and risk of oral submucous fibrosis, a pre-cancerous condition of oral cancer. J Dent Res 80 12 (2001) 2055-2059
78. Vairaktaris E., Serefoglou Z., Yapijakis C., Vassiliou S., Derka S., Nkenke E., et al. The interleukin-1 beta polymorphism +3953 C/T is not associated with risk for oral cancer. Anticancer Res 27 6B (2007) 3981-3986
79. Vairaktaris E., Serefoglou C.Z., Yapijakis C., Chatzitheofylaktou A., Vassiliou S., Nkenke E., et al. The Interleukin-18 -607A/C Polymorphism is not associated with risk for oral cancer. Anticancer Res 27 6B (2007) 4011-4014
80. Yapijakis C., Vairaktaris E., Vassiliou S., Vylliotis A., Nkenke E., Nixon A.M., et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133 10 (2008) 787-791
81. Vairaktaris E., Yannopoulos A., Vassiliou S., Serefoglou Z., Vylliotis A., Nkenke E., et al. Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 104 6 (2007) 796-802
82. Tsai M.H., Chen W.C., Tsai C.H., Hang L.W., and Tsai F.J. Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal 19 3 (2005) 93-98
83. Segal S., and Hill A.V. Genetic susceptibility to infectious disease. Trends Microbiol 11 9 (2003) 445-448
84. Pratesi C., Bortolin M.T., Bidoli E., Tedeschi R., Vaccher E., Dolcetti R., et al. Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55 1 (2006) 23-30
85. Ho S.Y., Wang Y.J., Huang P.C., Tsai S.T., Chen C.H., Chen H.H., et al. Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma. J Chin Med Assoc 69 8 (2006) 351-357
86. Wei Y.S., Kuang X.H., Zhu Y.H., Liang W.B., Yang Z.H., Tai S.H., et al. Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens 70 (2007) 12-17
87. Wei Y.S., Zhu Y.H., Du B., Yang Z.H., Liang W.B., Lv M.L., et al. Association of transforming growth factor-β1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 380 (2007) 165-169
88. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
89. Chen X., and Yang C.S. Esophageal adenocarcinoma: a review and perspectives on the mechanisms of carcinogenesis and chemoprevention. Carcinogenesis 22 8 (2001) 1119-1129
90. Savage S.A., Abnet C.C., Mark S.D., Qiao Y.L., Dong Z.W., Dawsey S.M., et al. Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13 12 (2004) 2251-2257
91. Savage S.A., Abnet C.C., Haque K., Mark S.D., Qiao Y.L., Dong Z.W., et al. Polymorphisms in Interleukin-2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk Chinese population. Cancer Epidemiol Biomark Prev 13 (2004) 1547-1549
92. Guo W., Wang N., Wang Y.M., Li Y., Wen D.G., Chen Z.F., et al. Interleukin-10-1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China. World J Gastroenterol 11 (2005) 858-862
93. Guo W., Wang N., Li Y., and Zhang J.H. Polymorphisms in tumor necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J 118 22 (2005) 1870-1878
94. Sin T., Miao X., Zhang X., Tan W., Xiong P., and Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Nt Cancer Inst 96 (2004) 1030-1036
95. Vairaktaris E, Yapijakis C, Serefoglou Z, Avgoustidis D, Critselis E, Spyridonidou S, et al. Gene expression polymorphisms of interleukins-1β, -4, -6, -8, -10, and tumor necrosis factors-α, -β: regression analysis of their effect upon oral squamous cell carcinoma. J Cancer Res Clinic Oncology [in press].
96. Miettinen M., Vuopio-Varkila J., and Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 64 (1996) 5403-5405
97. Schindler R., Mancilla J., Endres S., Ghorbani R., Clark S.C., and Dinarello C.A. Correlations and interactions in the production for interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppress IL-1 and TNF. Blood 75 (1990) 40-47
98. Yoshida S., Ono M., Shono T., Izumi H., Ishibashi T., Suzuki H., et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mod Cell Biol 17 7 (1997) 4015-4023
99. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376